Cargando…
Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy
Developing new therapeutic agents for cancer immunotherapy is highly demanding due to the low response ratio of PD-1/PD-L1 blockade in cancer patients. Here, we discovered that the novel immune checkpoint VISTA is highly expressed on a variety of tumor-infiltrating immune cells, especially myeloid d...
Autores principales: | Niu, Xiaoshuang, Wu, Menghan, Li, Guodong, Zhou, Xiuman, Cao, Wenpeng, Zhai, Wenjie, Wu, Aijun, Zhou, Xiaowen, Jin, Shengzhe, Chen, Guanyu, Li, Yanying, Du, Jiangfeng, Wu, Yahong, Qiu, Lu, Zhao, Wenshan, Gao, Yanfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638518/ https://www.ncbi.nlm.nih.gov/pubmed/37969728 http://dx.doi.org/10.1016/j.apsb.2023.08.003 |
Ejemplares similares
-
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020) -
Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT
por: Zhou, Xiaowen, et al.
Publicado: (2021) -
A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy
por: Yan, Zhongyi, et al.
Publicado: (2016) -
Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023) -
Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
por: Zhou, Xiuman, et al.
Publicado: (2020)